Overweight Clinical Trials in Houston, Texas

20 studies are recruiting for overweight in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   PlanIt Research /ID# 282204, Houston, Texas

   Locations

   45 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

   Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-2 Clinical Site, Houston, Texas

   Locations

   135 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743450 on ClinicalTrials.gov

3. AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

   This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the s…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Pulm Med Res Network, Houston, Texas

   Locations

   80 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07571005 on ClinicalTrials.gov

4. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Houston, Texas

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

5. AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

   This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will ei…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Pulm Med Res Network, Houston, Texas

   Locations

   92 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07571109 on ClinicalTrials.gov

6. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   PlanIt Research, PLLC, Houston, Texas

   Locations

   56 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

7. A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

   The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Biopharma Informatic, LLC, Houston, Texas

   Locations

   42 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07215559 on ClinicalTrials.gov

8. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Juno Research, Houston, Texas

   Locations

   157 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

9. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Juno Research, Houston, Texas

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07392190 on ClinicalTrials.gov

10. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    PlanIt Research, PLLC, Houston, Texas

    Locations

    74 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07533175 on ClinicalTrials.gov

11. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

    The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    PlanIt Research, LLC (Monitoring Room), Houston, Texas

    Locations

    50 in total

    Run by

    Pfizer

    See if you can join NCT07595549 on ClinicalTrials.gov

12. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    Stage

    Phase 3

    Ages

    45 to 99

    Site

    Biopharma Informatic, LLC, Houston, Texas

    Locations

    783 in total

    Run by

    Amgen

    See if you can join NCT07037433 on ClinicalTrials.gov

13. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    JCCT- Juno Northwest Houston, Houston, Texas

    Locations

    37 in total

    Run by

    Amgen

    See if you can join NCT07684144 on ClinicalTrials.gov

14. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    JCCT- Juno Northwest Houston, Houston, Texas

    Locations

    87 in total

    Run by

    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

15. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide …

    Stage

    Phase 3

    Ages

    8 to 18

    Site

    DM Clinical, Houston, Texas

    Locations

    121 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07253285 on ClinicalTrials.gov

16. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

    Stage

    Phase 3

    Ages

    6 to 17

    Site

    McGovern Medical School, Houston, Texas

    Locations

    117 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06672549 on ClinicalTrials.gov

17. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the…

    Stage

    Phase 3

    Ages

    12 to 17

    Site

    Dynamed Clinical Research, LP d/b/a DM Clinical Research, Houston, Texas

    Locations

    34 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06672939 on ClinicalTrials.gov

18. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

    Stage

    Phase 3

    Ages

    18 to 79

    Site

    ACCOMPLISH-1 Research Site, Houston, Texas

    Locations

    71 in total

    Run by

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654361 on ClinicalTrials.gov

19. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    PlanIt Research, PLLC, Houston, Texas

    Locations

    40 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07589608 on ClinicalTrials.gov

20. Semaglutide for Post-Smoking Cessation Weight Management

    This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    The University of Texas Health Science Center at Houston, Houston, Texas

    Locations

    2 in total

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT06173778 on ClinicalTrials.gov